Yinglong Miao, associate professor of pharmacology and computational medicine at the University of North Carolina at Chapel Hill, has been appointed editor-in-chief of npj Drug Discovery, an open-access publication. Dr. Miao will advance the journal’s mission of publishing innovative and high-quality research on all aspects of drug design and discovery.
After postdoctoral research at the University of California San Diego, Dr. Miao joined the University of Kansas in 2017 as an assistant professor and was promoted to associate professor in 2022. In 2023, Dr. Miao moved to UNC-Chapel Hill, where his UNC School of Medicine lab combines complementary simulations and experiments to uncover functional mechanisms and design drugs of important biomolecules, including G-protein-coupled receptors (GPCRs), membrane-embedded proteases, RNA-binding proteins, and RNA.
Nature is a weekly international journal publishing peer-reviewed research in all fields of science and technology and has been a top academic venue for science for over 100 years. npj Drug Discovery is part of the Nature portfolio of journals.
Key priorities of npj Drug Discovery include: publishing cutting-edge basic science as well as translational and clinical research on drug design and discovery; providing a unique forum for members of the drug discovery and design community to disseminate and discuss research findings across a broad range of disciplines; and highlighting studies involving all stages of drug development, including drug target identification, library screening, lead optimization, animal models and clinical trials.
The journal published a Q&A with Dr. Miao about his research and vision for the journal.
Click here to read the original press release.
